



1/12

1617

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

Gosse B. Bruinsma

**Serial No.:** 10/593,179

**Filed:** October 4, 2006 (presumed)

**For:** METHOD OF TREATING DOWN  
SYNDROME

**Examiner:** To be assigned

**Group Art Unit:** To be assigned

**Attorney Docket No.:** 3154-6272.1US

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

October 10, 2006  
Date

  
Signature

Betty Vowles  
Name (Type/Print)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
WO 03/082270 A1	10-09-2003	Axonyx, Inc.

Other Documents

Cure Research for Alzheimer's Disease, (visited 1/7/2004)

<[http://www.wrongdiagnosis.com/a/alzheimers\\_disease/research.htm](http://www.wrongdiagnosis.com/a/alzheimers_disease/research.htm)>.

PRASHER et al., A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--Pilot Study, International Journal of Geriatric Psychiatry, 2002, pp. 270-78, Vol. 17.

SHAW et al., Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development, PNAS, June 19, 2001, pp. 7605-10, Vol. 98, No. 13.

PATEL et al., Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor, Jan. 1998, pp. 171-76, Vol. 9, No. 1.

This Supplemental Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



Allen C. Turner  
Registration No. 33,041  
Attorney for Applicant  
TRASKBRITT, P.C.  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: October 10, 2006  
ACT/bv

Enclosures: Form PTO/SB/08  
Cited Non-U.S. Patent Documents  
Document in ProLaw

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	10/593,179
Filing Date	October 4, 2006 (presumed)
First Named Inventor	Gosse B. Bruinsma
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	3154-6272.1US

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/R.H./		Cure Research for Alzheimer's Disease, (visited 1/7/2004) < <a href="http://www.wrongdiagnosis.com/a/alzheimers_disease/research.htm">http://www.wrongdiagnosis.com/a/alzheimers_disease/research.htm</a> >.	
/R.H./		PRASHER et al., A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--Pilot Study, International Journal of Geriatric Psychiatry, 2002, pp. 270-78, Vol. 17.	
/R.H./		SHAW et al., Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development, PNAS, June 19, 2001, pp. 7605-10, Vol. 98, No. 13.	
/R.H./		PATEL et al., Abstract, Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor, Jan. 1998, pp. 171-76, Vol. 9, No. 1.	

Examiner  
Signature

/Raymond Henley III/

Date  
Considered

07/10/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.